MedPath

Evaluation of the effect of acetylene drug in comparison with oral administration of pantoprazole in controlling symptoms of gastro-esophageal reflux.

Phase 3
Conditions
Gastro-esophageal reflux.
Gastro-esophageal reflux disease
Registration Number
IRCT20180422039378N1
Lead Sponsor
Bagheiat-allah University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

Completion of informed consent form
Diagnosis of reflux disease is confirmed by clinical and paraclinical findings.
The patient's condition is not life-threatening.
Do not participate in another clinical trial at the same time.
Do not interact with medication before intervention. Like beta blocker inhibitors and herbal medicines or drugs that are harmful for treatment of reflux, such as theophylline, and others.
Age over 18 years
No smoking in the past
Not pregnancy
Failure to enter the plan for patients with psychiatric and veterinary injuries due to pulmonary symptoms

Exclusion Criteria

The occurrence of severe drug-related symptoms and severe hypersensitivity to drugs that can not be controlled.
Signs and symptoms of the patient have worsened during the study.
Those patients who have not consumed their medication for more than a week.
History of chemical gas and severe pulmonary disease.
Pregnant or intending to have a pregnancy
Presence and observation of drug interactions

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Symptoms of Gastro-esophageal reflux Disease. Timepoint: Before starting treatment, as well as at 3 and 6 weeks after starting treatment. Method of measurement: Interview with patients using reflux symptom index questionnaire.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath